Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
Source: View publication →
In this phase 3 trial, daily oral semaglutide 50 mg significantly reduced body weight compared with placebo over 68 weeks in adults with overweight or obesity without type 2 diabetes.
Key Findings
Study Design
Study Limitations
Clinical Significance
This trial demonstrates that a high-dose oral formulation of semaglutide (50 mg) is an effective, once-daily therapeutic option for weight management in patients with overweight or obesity, offering an alternative to injectable GLP-1 receptor agonists for patients with specific administration preferences.
Historical Context
While once-weekly injectable semaglutide 2.4 mg (Wegovy) previously established a high standard for pharmacological weight management, the OASIS 1 trial explored whether a high-dose oral formulation could achieve comparable efficacy, addressing the clinical need for non-injectable options in this therapeutic class.
Guided Discussion
High-yield insights from every perspective
How does the co-formulation with sodium salcaprozate (SNAC) allow a peptide like semaglutide to be absorbed orally, and what are the primary physiological mechanisms by which GLP-1 receptor agonists induce weight loss?
Key Response
Peptides are typically degraded by gastric acid and proteases. SNAC acts as an absorption enhancer by locally increasing pH to protect semaglutide from pepsin and promoting its transcellular absorption across the gastric epithelium. Weight loss is primarily achieved through central nervous system modulation of satiety and hunger in the hypothalamus, alongside delayed gastric emptying.
In clinical practice, what are the specific administration requirements for oral semaglutide 50 mg that must be communicated to patients to ensure efficacy, and how do the gastrointestinal side effects observed in OASIS 1 influence the titration schedule?
Key Response
Oral semaglutide must be taken on an empty stomach upon waking with no more than 120 mL of plain water, followed by at least a 30-minute fast to ensure absorption. In OASIS 1, dose escalation (starting at 3 mg and moving to 50 mg) was used to mitigate the high frequency of GI side effects (nausea, constipation, diarrhea) which are most prevalent during the titration phase.
Comparing the OASIS 1 results (oral 50 mg) to the STEP 1 trial (subcutaneous 2.4 mg), the weight loss percentages are remarkably similar (15.1% vs 14.9% estimated treatment policy). What pharmacological factors explain why a 50 mg oral dose is required to achieve parity with a 2.4 mg subcutaneous dose, and how should this influence the management of patients with malabsorptive conditions?
Key Response
The oral bioavailability of semaglutide is extremely low (approximately 0.4–1.0%), necessitated by the harsh gastric environment despite SNAC. This requires a much higher molar dose (50 mg daily vs 2.4 mg weekly). Patients with history of bariatric surgery or significant gastrointestinal motility disorders were excluded from the trial, suggesting caution and potentially prioritizing subcutaneous routes in those with altered gut anatomy or absorption.
OASIS 1 demonstrated significant weight loss, but the 'treatment policy estimand' showed a lower effect size than the 'trial product estimand' (15.1% vs 17.4%). How should this distinction inform your counseling of a patient who is hesitant about the long-term commitment to a daily high-dose oral peptide?
Key Response
The treatment policy estimand reflects real-world outcomes including those who stopped the drug, while the trial product estimand reflects the biological potential if taken perfectly. The attending must highlight that while the drug is highly effective, the 'real-world' 15% loss accounts for the ~13% discontinuation rate (mostly due to adverse events), emphasizing that persistence is key to achieving the higher efficacy figures.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The OASIS 1 trial utilized a double-dummy design to maintain blinding. Critically evaluate the impact of this design on the assessment of patient-reported outcomes (PROs) and whether the high rate of gastrointestinal side effects in the treatment arm could have led to 'unblinding' by participants, potentially biasing the subjective weight-related quality of life scores.
Key Response
Since 80% of the treatment group experienced GI side effects compared to 46% of the placebo group, participants may have correctly guessed their assignment. This 'unblinding' effect can inflate PROs related to treatment satisfaction and perceived efficacy. Future trials might consider active placebos or sensitivity analyses that adjust for the presence of side effects when reporting subjective quality-of-life improvements.
Given the 68-week duration of OASIS 1, to what extent can we conclude that the weight loss had truly plateaued, and does the safety data provided allow for a robust assessment of rare but serious risks like pancreatitits or medullary thyroid carcinoma in a non-diabetic population?
Key Response
While the weight loss curve was flattening, some slope remained at week 68, suggesting maximum efficacy might require longer observation. Furthermore, for a 50 mg dose—nearly four times the highest approved T2DM dose—the sample size (N=667) is insufficient to exclude rare but serious GLP-1 associated risks, necessitating a call for larger post-marketing surveillance data in the editorial commentary.
The 2022 AHA/ACC/TOS and 2023 AACE guidelines emphasize GLP-1 RAs for obesity. How does the emergence of a 50 mg oral formulation change the hierarchy of recommendations currently dominated by subcutaneous semaglutide and tirzepatide, particularly regarding health equity and resource-limited settings?
Key Response
Current guidelines prioritize efficacy and metabolic co-morbidities. While oral semaglutide 50 mg offers a non-invasive alternative with similar efficacy to SQ semaglutide 2.4 mg, its daily dosing and strict fasting requirements may affect adherence. Guideline updates must now weigh the benefit of 'needle-free' options against the likely higher cost of goods for high-dose oral peptides and the potential for reduced efficacy if administration protocols are not strictly followed.
Clinical Landscape
Noteworthy Related Trials
PIONEER 1 Trial
Tested
Oral semaglutide (3, 7, or 14 mg daily)
Population
Adults with type 2 diabetes
Comparator
Placebo
Endpoint
Change in HbA1c from baseline to week 26
STEP 1 Trial
Tested
Subcutaneous semaglutide 2.4 mg once weekly
Population
Adults with overweight or obesity without diabetes
Comparator
Placebo
Endpoint
Percentage change in body weight from baseline to week 68
OASIS 2 Trial
Tested
Oral semaglutide 50 mg once daily
Population
Adults with type 2 diabetes and overweight or obesity
Comparator
Placebo
Endpoint
Percentage change in body weight from baseline to week 68
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis